Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310244 · ClinicalTrials.gov registry record · Phase 1
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
A Phase 1 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01310244 is a Phase 1 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 23 participants.
The verdict
NCT01310244, a Phase 1 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
Interventions
- DRUG Belinostat, Carboplatin, Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310244
The ClinicalTrials.gov registry entry for NCT01310244 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belinostat, Carboplatin, Paclitaxel is the first listed.
NCT01310244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01310244 about?
NCT01310244 is a clinical study titled "MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC". To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
What is the current status of trial NCT01310244?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2010-12. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01310244?
The interventions under investigation include: Belinostat, Carboplatin, Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01310244?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.